[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Brigham and Women's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":600},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,195,0,25,[9,43,75,101,116,144,167,189,213,238,262,286,308,327,345,368,388,413,437,454,477,496,520,554,577],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054006",false,"NCT02193542","Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients","Prospective Observation Study of Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients","DADB","Inclusion Criteria:\n\n* Pregnant woman presenting for vaginal or cesarean delivery\n\nExclusion Criteria:\n\n* Pregnant woman presenting for vaginal or cesarean delivery requiring urgent or emergent delivery",true,"FEMALE",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Anesthesiologists commonly administer pain relief during labor or providing anesthesia for cesarean delivery. Two main methods are used to achieve these goal: \"Regional anesthesia\" where the mother is given medication through a needle or catheter in her back and the mother is kept awake, or \"General anesthesia\", where the mother is given intravenous medication and is kept asleep.\n\nRegional anesthesia uses a needle to enter a narrow space in the mother's back where medications can be given. In some patients, it takes longer to find this target space in the back. In emergency situation, however, there is often little time to find this space, and the backup method would be the general anesthesia technique.\n\nIf general anesthesia is required, a breathing tube needs to be inserted to help support the mother's breathing. In some patients, it is harder to insert the breathing tubes, so knowing this in advanced helps anesthesiologists create a safe plan for the patients. A lot of research has been done to determine factors that would predict which patients would need more time and preparation for general anesthesia and regional anesthesia.\n\nThe purpose of this study is to study how common it is for the pregnant patients who have a difficult regional and general anesthesia.",[25],"Indication for Care or Intervention Related to Labor or Delivery With Baby Delivered",[27,28,29],"regional anesthesia","general anesthesia","obstetric","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2014-07-01",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Brigham and Women's Hospital","OTHER",1,{"id":44,"slug":4,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100054051","NCT07043738","Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial","NNS","Inclusion Criteria:\n\n* Age 22-80\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of major depressive disorder per DSM-V criteria (Quick Structured Clinical Interview for DSM-5)\n\n  * \\>20 on Beck Depression Inventory (BDI)\n  * \\>20 on the Montgomery-Åsberg Depression Rating Scale (MADRS)\n  * Moderate to severe level of treatment resistance (Maudsley Staging Method)\n* Stable antidepressant medication regimen, or remain medication free, for 4 weeks prior to treatment and to remain on this regimen throughout the study until the 1-month post-treatment visit.\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n* Agreement to lifestyle considerations\n\n  * Abstain from becoming pregnant from screening to one-month after treatment (the MRI visit)\n  * Continue usual intake patterns of caffeine- or xanthine-containing products (e.g. coffee, tea, soft drinks, chocolate) throughout treatment\n  * Abstain from alcohol, tobacco, and recreational drugs for at least 24 hours before the start of each MRI and TMS session","ALL","22 Years","80 Years",{"count":53,"type":21},160,"INTERVENTIONAL",[56],"NA","Transcranial magnetic stimulation(TMS) is a non-invasive form of brain stimulation that is cleared by the United States Food and Drug Administration (FDA) for depression. Conventional TMS involves daily weekday treatments for 6-8 weeks. These treatments are targeted using each person's scalp measurements. With conventional TMS, approximately 50-55% of people show a 50% or more improvement in depressive symptoms (in other words, they \"respond\" to treatment).\n\nStudies are trying to make TMS work better and faster. A new form of TMS called accelerated TMS (aTMS) involves mutliple treatments a day. One specific aTMS protocol involves 10 treatments per day for 5 days. These treatments are targeted using each person's brain scan (magentic resonance imaging, MRI). With this specific aTMS protocol, approximately 70-90% of people show a 50% or more imporvement in depressive symptoms. While these results are exciting, scientists are not sure why this specific aTMS protocol works better than conventional TMS. It could be the dose and schedule of treatment, or it could be the MRI-based targeting. Answering this question is important because MRI-based targeting is expensive and difficult to do in many settings.\n\nThis study aims to determine if MRI-based targeting is better than scalp-based targeting for aTMS for depression. In this study, everyone who enrolls and meets criteria will be randomly assigned to MRI- versus scalp-based aTMS targeting.",[59],"Major Depressive Disorder (MDD)",[61,62,63,64,65,66,67],"Accelerated Transcranial Magnetic Stimulation","Depression","Major Depressive Disorder","Treatment resistant depression","TMS","Transcranial Magnetic Stimulation","Neuromodulation","NOT_YET_RECRUITING",{"date":33,"type":34},{"date":71,"type":21},"2026-08-03",{"date":73,"type":21},"2032-08",{"name":40,"class":41},{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":54,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":42},"100054108","NCT05543694","ED90 of Epidural Bupivacaine With Lidocaine for the Initiation of Labor Analgesia","ED90 of Epidural Bupivacaine for the Initiation of Labor Analgesia: A Randomized Biased Coin Sequential Allocation Trial With a Lidocaine Test Dose","Inclusion Criteria:\n\n* Parturient with no major co-morbidities\n* Singleton, vertex gestation at term (37-42 weeks)\n* Less than or equal to 5 cm dilation\n* Desire to receive epidural labor analgesia\n* Numerical Rating Scale greater or equal to 5 (NRS 0-10, where 0 = no pain, and 10 = worst pain imaginable), at time of epidural labor analgesia request.\n\nExclusion Criteria:\n\n* Current or historical evidence of clinically significant disease or condition, including diseases of pregnancy (i.e preeclampsia, gestational diabetes)\n* Any contraindication to the administration of an epidural technique\n* History of hypersensitivity or idiosyncratic reaction to an amide local anesthetic agent\n* Current or historical evidence of a disease which may result in the risk of a cesarean delivery (i.e. history of uterine rupture). NB: Exception-trial of labor after cesarean delivery (TOLAC) will be eligible.\n* Evidence of anticipated fetal anomalies","18 Years","50 Years",{"count":84,"type":21},120,[86],"PHASE4","To estimate the dose of bupivacaine required to achieve initial effective comfort in 90% of patients (ED90) via the epidural (DPE or EPL) technique in women undergoing labor after receiving a lidocaine \"test dose\"",[89,90],"Labor Pain","Analgesia",[92,93,94,95],"Dural puncture epidural","Neuraxial Analgesia","Bupivacaine","Local Anesthetic",{"date":33,"type":34},{"date":98,"type":34},"2022-10-01",{"date":38,"type":21},{"name":40,"class":41},{"id":102,"slug":4,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":54,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":42},"100054320","NCT06146842","ED90 of Bupivacaine After Lidocaine Test Dose With DPE and EPL","A Trial to Determine the Optimal Bupivacaine Dose for Initiation of Labor Epidural Pain Relief With a Lidocaine Test Dose","Inclusion Criteria:\n\n1. Parturient with no major co-morbidities\n2. Singleton, vertex gestation at term (37-42 weeks)\n3. Less than or equal to 5 cm dilation\n4. Desire to receive epidural labor analgesia\n5. Numerical Rating Scale greater than or equal to 5 (NRS 0-10, where 0 = no pain, and 10 = worst pain imaginable), at time of epidural labor analgesia request.\n\nExclusion Criteria:\n\n1. Current or historical evidence of clinically significant disease or condition, including diseases of pregnancy (i.e., preeclampsia, gestational diabetes)\n2. Any contraindication to the administration of an epidural technique (e.g., thrombocytopenia, antiplatelet meds).\n3. History of hypersensitivity or idiosyncratic reaction to an amide local anesthetic agent\n4. Evidence of anticipated fetal complications (i.e., fetal anomalies, IUGR (Intrauterine Growth Restriction), oligohydramnios, polyhydramnios)",{"count":84,"type":21},[86],"The primary objective of our study is to use a biased coin up-down allocation methodology to estimate the dose of bupivacaine required after the lidocaine test dose to achieve initial effective comfort in 90% of patients (post test-dose ED90) via the epidural (DPE or EPL) technique in women undergoing labor induction or augmentation; the investigators hypothesize that the investigators will be able to determine the post test-dose ED90 of bupivacaine for each technique with adequate precision to inform the optimal doses to study in a subsequent randomized trial comparing the analgesic effects of DPE vs. EPL. The investigators also hypothesize that the post test-dose ED90 of bupivacaine is lower with a DPE technique than with a conventional epidural technique.",[89],{"date":33,"type":34},{"date":113,"type":34},"2023-12-01",{"date":38,"type":21},{"name":40,"class":41},{"id":117,"slug":4,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":17,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100645256","NCT07681895","Biophysical Assessments of Acupuncture Points in Inflammatory Bowel Disease","Acupoint Sensitization in Inflammatory Bowel Disease: A Non-interventional Study","Inclusion Criteria (Adults with IBD):\n\n* adults (age 18 years or older)\n* clinical diagnosis of ulcerative colitis or Crohn's disease\n\nExclusion Criteria (Adults with IBD):\n\n* any history of serious musculoskeletal or soft tissue injury of the lower and\u002For upper extremities\n* presence of scarring or tattoo on the lower and\u002For upper extremities\n* presence of serious cardiac diseases, severe dermatological conditions, peripheral neuropathy, infectious disease, psychological illnesses, or other serious co-morbidities (e.g., cancer)\n* prior history of colostomy or ileostomy\n* pregnancy\n\nInclusion Criteria (Healthy control participants):\n\n\\- adults (age 18 years or older) in good health conditions\n\nExclusion Criteria (Healthy control participants):\n\n* history of chronic inflammatory diseases, such as IBD\n* severe digestive and\u002For intestinal conditions, such as irritable bowel syndrome (IBS)\n* any history of serious musculoskeletal or soft tissue injury of the lower and\u002For upper extremities\n* presence of scarring or tattoo on the lower and\u002For upper extremities\n* presence of serious cardiac diseases, severe dermatological conditions, peripheral neuropathy, infectious disease, psychological illnesses, or other serious co-morbidities (e.g., cancer)\n* pregnancy",{"count":123,"type":21},100,"Acupuncture points or acupoints are fundamental to the practice of acupuncture, yet their scientific basis remains unclear. According to traditional explanations of acupuncture, acupoints can become tender or more sensitive to pressure when there is an underlying disease of the body. Findings from recent basic animal studies support this traditional theory. For example, compared to healthy control animals, models of colitis have shown increased skin temperature, blood flow, and pain sensitivity at specific body regions that correspond to the location of acupoints that are commonly used in acupuncture treatment for colitis. However, little is known about whether these findings apply to humans.",[126],"Inflammatory Bowel Disease (IBD)",[128,129,130,131,132,133,134,135],"Inflammatory bowel disease","IBD","Acupuncture point","Acupoint","Cutaneous neurogenic inflammation","Infrared thermography","Laser speckle contrast imaging","Pressure pain threshold","2026-06-27",{"date":138,"type":34},"2026-07-02",{"date":140,"type":21},"2026-08-01",{"date":142,"type":21},"2027-11-30",{"name":40,"class":41},{"id":145,"slug":4,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":42},"100606318","NCT07173998","Quality of Life in Patients With Postoperative Atrial Fibrillation After Cardiac Surgery","Prospective Observational Study on Quality of Life With Postoperative Atrial Fibrillation","Inclusion Criteria:\n\n* All genders\n* Ages 18-99 years old\n* Scheduled to undergo cardiac surgery\n* Able to answer survey questions\n\nExclusion Criteria:\n\n* Persistent \u002F permanent atrial fibrillation\n* Atrial fibrillation at presentation for surgery\n* Emergent operations","100 Years",{"count":152,"type":21},260,"Prospective observational study on quality of life with postoperative atrial fibrillation after cardiac surgery using SF-36 and qualitative questions",[155],"Postoperative Atrial Fibrillation",[157,158],"cardiac surgery","recovery","2026-06-26",{"date":161,"type":34},"2026-06-29",{"date":163,"type":34},"2025-07-15",{"date":165,"type":21},"2027-07-01",{"name":40,"class":41},{"id":168,"slug":4,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":49,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100430068","NCT04880265","Assessing the Burden of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Elective open heart surgery\n* Age \\> 20 years\n\nExclusion Criteria:\n\n* Refusal to participate (patient or health care proxy)\n* Participation in other pharmacological trials\n* Lack of data or poor data quality which cannot be analyzed for any heart rhythm in 80% of the postoperative study period.","20 Years","90 Years",{"count":175,"type":21},150,"Background and Significance:\n\nIn the United States approximately 220,000 patients undergo cardiac surgery per annum. Among potential complications, the incidence of atrial fibrillation (AF) is estimated at 30 - 60 %, and therefore presents the most common adverse event after cardiac surgery. Multiple complications may be associated with AF: Patients are usually subject to an increased length-of-stay in the intensive care unit and in the hospital. Furthermore, the risk for stroke and development of long-term AF is elevated, while further anticoagulation is required putting the patient at risk for bleeding. On average, an additional $10,000 - $20,000 is spent for each patient with AF. However, the exact burden of postoperative AF still remains unknown.\n\nSpecific Aims of Research Project:\n\n1. To collect data from an electrocardiogram (EKG) monitoring patch, we aim to accurately determine the prevalence of atrial fibrillation in patients undergoing cardiac surgery at our center.\n2. To collect data on epidemiological characteristics to investigate risk factors for developing perioperative atrial fibrillation in patients undergoing cardiac surgery. This will allow us to create robust risk prediction models.",[178,179],"Atrial Fibrillation","Cardiac Surgery",[181],"Wearable Device",{"date":183,"type":34},"2026-06-30",{"date":185,"type":34},"2021-09-14",{"date":187,"type":21},"2030-05",{"name":40,"class":41},{"id":190,"slug":4,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":54,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100578202","NCT06808230","Cocoa Extract for Migraine Trial","Cocoa Flavanols for Migraine: A Pilot Study","CORAL","Inclusion Criteria:\n\n* Women and men aged ≥18 years\n* Self-reported clinician diagnosis of migraine with or without aura which does not meet criteria for chronic migraine (according to the International Classification of Headache Disorders 3rd edition)\n\n  * Individuals with self-reported migraine will need to report a clinician diagnosis of migraine and be classified as having migraine or probable migraine by the American Migraine Study (AMS) migraine screener. The AMS migraine screener, which has a sensitivity of 100% and a specificity of 82% for the diagnosis of migraine will be used to confirm self-reported migraine status.\n  * History of migraine dating for at least one year\n* Self-report of 4 to 14 migraine attacks during the 30 days prior to enrollment in the study\n* Completion of at least 22 headache diary days during the 28 day run-in period\n\n  o Report migraine frequency between 4 to 14 days during the 28 day run-in period\n* If currently using medications to prevent or treat migraine, no new medication use within the past 3 months\n* No new use of behavioral interventions within the past 3 months and\u002For agree to not begin new behavioral interventions during this trial\n* Be willing to complete all study procedures and be randomized to all interventional groups\n* Be fluent in English\n* Own an iPhone or Android device and be willing to download MyCap to the device\n\nExclusion Criteria:\n\n* Self-reported history of stroke or transient ischemic attack; history of brain surgery or spine surgery; currently receiving treatment for a concussion; and self-reported diagnosis of cluster headache, brain tumor, brain aneurysm, traumatic brain injury, multiple sclerosis, epilepsy, schizophrenia, or bipolar disorder\n* Kidney failure or current dialysis treatment or any medical condition which the participant believes could lead to difficulty complying with the protocol\n* Current alcohol or substance abuse (self-reported)\n* Self-reported clinician diagnosis of medication overuse headache\n* Currently or recently (past 6 months) received Botox treatment for migraine\n* Failure to return the baseline urine sample\n* Currently pregnant, nursing, or intending to become pregnant during the study period.\n* Unwilling to forgo use of out-of-study supplements of cocoa extract during the trial\n* Extreme sensitivity to caffeine",{"count":197,"type":21},114,[56],"The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are:\n\n* Will we be able to enroll 114 participants during the recruitment period?\n* Will participants take study pills daily during the pill-taking period?\n\nResearchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population.\n\nParticipants will be asked to:\n\n* Provide two urine samples\n* Complete daily questionnaires\n* Take four study pills a day for 12 weeks",[201],"Migraine",[203,204,205],"migraine","cocoa extract","cocoa flavanol","2026-06-25",{"date":161,"type":34},{"date":209,"type":34},"2025-06-23",{"date":211,"type":21},"2026-12-01",{"name":40,"class":41},{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":54,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100629046","NCT07469553","Chiropractic Care for Chronic Neck Pain: A Pilot Study","Chiropractic Care for Chronic Neck Pain: A Pilot Randomized Controlled Trial Evaluating Feasibility, Clinical Outcomes, and EEG\u002FGait Biomarkers","Inclusion Criteria:\n\nAdults aged 18-65 years Diagnosis of CNP (e.g., nociceptive, neuropathic, or nociplastic origin) occurring ≥5 days per week for ≥3 consecutive months.\n\nAverage neck pain intensity ≥3 on a 0-10 Numerical Rating Scale (NRS) during the past week (0 = no pain at all; 10 = worst neck pain imaginable).\n\nNeck Disability Index (NDI) score ≥5 \\[37\\] 10-item instrument with scores ranging from 0 (no disability) to 50 (complete disability).\n\nWillingness to complete all study procedures. Willingness to be randomized to either of the two intervention groups. Fluent in English.\n\nExclusion Criteria:\n\n* Currently receiving chiropractic care or have received chiropractic care within the past 12 months.\n\nParticipation in ≥1 session per week of mind-body or rehabilitation therapies (e.g., physical therapy, yoga, tai chi, Qigong) within the past 12 months.\n\nAny disability precluding exercise participation. Pregnancy. Pregnancy status will be assessed by self-report only. No pregnancy testing will be conducted for the purposes of this study.\n\nPrior cervical spine surgery or any spinal surgery within the past year. Active disability or accident-related compensation claim. Signs or symptoms of major systemic illness or unstable medical conditions (e.g., Parkinson's disease, cancer).\n\nPsychiatric conditions requiring immediate treatment or likely to impair protocol compliance.\n\nCNP attributable to on-neuromusculoskeletal source. Inflammatory arthritis. History of stroke, carotid dissection, or vertebral artery dissection. Presence of a neurological disorder. Suspected or confirmed pathological hypermobility. Receipt of interventional pain management to the cervical spine within 4 weeks prior to enrollment or planned during the study period.\n\nAvailable diagnostic imaging demonstrating contraindications to study treatments (e.g., cervical myelopathy, substantial disc derangement).\n\nClinical screening findings indicating a need for diagnostic imaging. High risk for adverse events (AEs) related to any study treatment. Inadequate transportation to attend scheduled study visits. Contraindications to standard, non-invasive scalp EEG procedures (e.g., open scalp wounds, active skin infections, or unhealed surgical sites at electrode placement locations; recent craniotomy or skull defect that would interfere with safe electrode placement, Implanted neurostimulation devices; known seizure disorders or epilepsy; medical conditions for which EEG activation procedures are contraindicated (stroke, hyperventilation).","65 Years",{"count":221,"type":21},60,[56],"This pilot randomized controlled trial will evaluate the feasibility and preliminary clinical effects of multimodal chiropractic care for adults with chronic neck pain. Forty participants will be randomized to receive either multimodal chiropractic care plus enhanced usual care or enhanced usual care alone. Feasibility outcomes include recruitment, retention, adherence, and safety. Clinical outcomes include pain intensity, neck-related disability, physical and psychological function, and quality of life. Exploratory electroencephalography (EEG) and gait assessments will examine potential neurophysiological and biomechanical biomarkers associated with treatment response.",[225],"Neck Pain",[227,228,229,230,231],"neck pain","chiropractic care","EEG","gait","randomized trial","2026-06-24",{"date":159,"type":34},{"date":140,"type":21},{"date":236,"type":21},"2027-09-30",{"name":40,"class":41},{"id":239,"slug":4,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":54,"phases":246,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},"100614353","NCT07278492","NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome","Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome","Inclusion Criteria:\n\n1. A diagnosis of full trisomy for chromosome 21 or complete unbalanced translocation of chromosome 21, confirmed by karyotype analysis or clinical documentation.\n2. 18 years or older\n3. Participant has a caregiver\u002F informant who has direct contact with the participant \\>10 hours\u002F week and who can provide information about participant's health\n4. Participant or Legal Authorized Representative is able to understand and willing to provide written informed consent and capable of completing study assessments.\n5. In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months.\n\nExclusion Criteria\n\n1. Fasting morning UACR \\> 5,000 mg\u002F g creatinine\n2. Other laboratory abnormalities:\n\n   1. Has AST or ALT \\> 3 times the upper limit of normal\n   2. eGFR \\\u003C 30 mL\u002F min \u002F 1.73 m2\n   3. Hematocrit \\\u003C 0.34 or \\> 0.50 L\u002FL\n3. A major adverse cardiovascular event in preceding 3 months\n4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter\n5. Current alcohol or substance use disorder or dependence (DSM 5 criteria).\n6. Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures.\n7. An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month.\n8. Has a history of anaphylaxis from vitamin B3 derivatives\n9. BMI \\> 42.5 kg\u002F m2\n10. Non-ambulatory",{"count":245,"type":21},24,[247],"PHASE1","The aim of the study is to determine the safety and tolerability of different increasing doses of MIB-626 (a microcrystalline form of β nicotinamide mononucleotide; NMN) given daily for 28 consecutive days to adults with Down syndrome (DS). The study will also explore how the drug moves through the body over time (pharmacokinetics or PK) and how the drug affects the body in different ways (pharmacodynamics or PD). The study participants will be monitored for adverse events and measurements to detect safety events will take place including laboratory tests of blood counts, chemistries and coagulation profile, and electrocardiogram (ECG). The trial will enroll a total of 24 adults with DS who are 18 years or older and are medically stable. People enrolled in the study will be randomly assigned to receive either the active intervention (MIB-626) tablets, or placebo tablets for 28 days. Study participants will be followed for an additional 28 days (total 56 days of follow-up). This study will also explore the effect of MIB-626 on different measures associated with aging and risk of Alzheimer's Disease (AD).",[250],"Down Syndrome (DS)",[252,253,254],"Down Syndrome","NMN","safety",{"date":206,"type":34},{"date":257,"type":21},"2026-07-31",{"date":259,"type":21},"2028-06-30",{"name":40,"class":41},2,{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":54,"phases":270,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":42},"100593988","NCT07013591","Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)\n3. At increased risk of postoperative complications based on ≥1 of the following:\n\n   1. Age ≥65 years\n   2. eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2\n   3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery\n   4. Diabetes mellitus and urine albumin-to-creatinine ratio \\>30 mg\u002Fg creatinine\n   5. Peripheral arterial disease\n   6. Anemia, defined as hemoglobin \\\u003C10 g\u002Fdl\n   7. Prior cardiac surgery\n\nExclusion Criteria:\n\n1. Any of the following laboratory abnormalities at the time of screening:\n\n   1. ALT \\>3-fold the upper limit of normal\n   2. eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 or ESKD on dialysis\n   3. Hemoglobin \\\u003C8 g\u002Fdl\n2. History of gastric bypass or malabsorption\n3. Active alcohol or illicit substance use in the prior 6 months\n4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter\n5. Pregnant or breast-feeding\n6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential\n7. Current use of niacin \\>100 mg\u002Fday or NMN, nicotinamide, or nicotinamide riboside at any dose\n8. Conflict with other research studies\n9. Any condition which, in the judgement of the investigator, might increase the risk to the participant",{"count":269,"type":21},90,[271],"PHASE2","The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.",[274],"Coronary Artery Bypass Graft",[276,157,277,278,253,279],"coronary artery bypass graft","cardiopulmonary bypass","nicotinamide","acute kidney injury",{"date":159,"type":34},{"date":282,"type":34},"2026-06-10",{"date":284,"type":21},"2029-01-01",{"name":40,"class":41},{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":49,"minAge":219,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":54,"phases":294,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":42},"100592012","NCT06987890","Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy","Lung-GAP","Inclusion Criteria:\n\n* Age ≥ 65 years old at time of study enrollment.\n* Radiographically or pathologically confirmed stage I-II non-small cell lung cancer.\n* All patients must have undergone appropriate complete imaging of their cancer consistent with the standard of care.\n* Patient is expected to undergo stereotactic body radiation therapy (SBRT)\n* Able to read questions in English or willing to complete survey questionnaires with the assistance of an interpreter.\n\nExclusion Criteria:\n\n* There are no exclusion criteria.",{"count":293,"type":21},64,[56],"National guidelines recommend that older adults with cancer undergo a special health assessment before starting cancer treatment. This type of assessment evaluates physical function, nutrition, social support, psychological well-being, medical conditions (both cancer-related and non-cancer-related), and cognitive function. The results can help doctors make better treatment decisions and determine whether additional support services-such as nutrition counseling, physical therapy, or social work-would be beneficial. Even though these assessments are recommended, they are not typically used because they need to be performed by a specialist and can take over an hour to complete. Given these challenges, a 10-15-minute assessment called the Practical Geriatric Assessment (PGA) was recently developed. The PGA can be completed by any healthcare provider and helps identify older adults who may need extra support alongside their cancer treatment. While the PGA has the potential to make geriatric assessments more accessible, the investigators do not yet know whether patients will find it useful or easy to complete.\n\nAdditionally, it is unclear whether using the PGA will lead to more referrals for recommended supportive care services. This study aims to address these questions. The investigators will evaluate whether using the PGA impacts the number of patients referred to recommended supportive care services. Investigators will also evaluate how participants feel about completing the PGA, including how easy or difficult it is, and to assess the feasibility of implementing this survey on a larger scale. Finally, the investigators will use facial photographs and audio-visual data from the PGA to develop and evaluate artificial intelligence algorithm(s) to identify vulnerable patients who might benefit from additional supportive care services; namely, FaceAge, a validated deep learning model capable of estimating biological age from still facial images.",[297,298,299],"Lung Cancer (NSCLC)","Geriatric Assessment","Stereotactic Body Radiation Therapy (SBRT)",[301,302],"Lung Cancer","Geriatric",{"date":206,"type":34},{"date":305,"type":34},"2025-05-26",{"date":159,"type":21},{"name":40,"class":41},{"id":309,"slug":4,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":54,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":42},"100550018","NCT06441604","Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","Inclusion Criteria:\n\n* English speaking adults aged 18 and above.\n* diagnosis of opioid use disorder.\n* Self-reporting use of illicit opioids in \\>21 days in the prior 30 days.\n* Provide urine toxicology testing positive for fentanyl at baseline.\n\nExclusion Criteria:\n\n* Seeking medication treatment for opioid use disorder with sublingual buprenorphine or methadone.\n* Received buprenorphine or methadone treatment in prior 30 days.\n* Current diagnosis of alcohol or sedative\u002Fhypnotic use disorder.\n* Positive urine drug screen for benzodiazepines, alcohol and or methadone.\n* Physical dependence on alcohol or sedative\u002Fhypnotics.\n* Psychotic disorder, active suicidality or homicidally or any psychiatric condition that impair ability to provide informed consent.\n* Have a history or diagnosis of Intracranial mass\u002Fbleed, seizure disorder, liver cirrhosis, renal failure, obstructive lung disease, hyperthyroidism, narrow-angle glaucoma, valvular heart disease, cardiac arrhythmias, heart failure.\n* Recent (within 6 months) head trauma, stroke, or myocardial infarction\n* Requiring treatment with opioids for acute or chronic pain.\n* History of hypersensitivity or allergy to buprenorphine or fentanyl.\n* Pregnant or breastfeeding.\n* Liver function test greater than 3 times upper normal limit.\n* Receiving medications that are strong or moderate CYP34A inducers or inhibitors (including but not limited to ketoconazole, itraconazole, clarithromycin, fluconazole, erythromycin), in the past 30 days.",{"count":314,"type":21},30,[271],"This is a clinical trial to characterize the safety and pharmacokinetics of using extended-release buprenorphine (XR-BUP) as a novel low-dose buprenorphine induction strategy. Individuals with a diagnosis of Opioid Use Disorder (OUD) (n=30) will be admitted to an inpatient unit to complete study procedures over the course of 3 days. Participants will receive fentanyl to prevent the emergence of withdrawal. Each participant will then receive a single injection of XR-BUP after which study staff will monitor for any precipitated withdrawal.",[318],"Opioid Use Disorder",[318,320],"Buprenorphine",{"date":159,"type":34},{"date":323,"type":34},"2025-10-27",{"date":325,"type":21},"2027-01-31",{"name":40,"class":41},{"id":328,"slug":4,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":219,"enrollmentInfo":332,"targetDuration":4,"studyType":54,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":42},"100533747","NCT06229834","Chiropractic Care for Episodic Migraine","Inclusion Criteria\n\n* Age 18-65 years\n* Confirmed diagnosis of migraine with or without aura which does not meet criteria for chronic migraine according to the International Classification for -Headache Disorders (ICHD)-3 guidelines at the screening visit with the study physician\n* History of migraines dating for at least one year\n* Completion of at least 26 headache diary days out of 28\n* Confirmed migraine frequency ≥4 to ≤13 days per month during a run-in period\n* If use of medication is applicable, dose must be stable for 2 months prior to study enrollment\n* If use of medication for non-migraine pain condition is applicable (with the exception of episodic tension type headache), dose must be stable for 2 months prior to study enrollment\n* Willing and able to complete all study procedures and be randomized to either of the two intervention groups\n* Fluency in English\n* Confirmed access to and proficiency with use of a smartphone, computer, and\u002For tablet\n* Working email address or willingness to create an email account for the study\n\nExclusion Criteria\n\n* Non-Veterans (VAMC only)\n* Received botulinum toxin treatment for headache and\u002For neck pain within the 4 months prior to the start of the baseline phase\n* Received chiropractic care for any condition within the 3 months prior to the start of the baseline phase\n* Received behavioral interventions (e.g., cognitive behavioral therapy, acceptance and commitment therapy, mindfulness, relaxation techniques, hypnosis) within the past 3 months)\n* Used neuromodulation (i.e., \"headache devices\"), procedures for migraine prevention within the 2 months before the baseline period, or investigational medications or headache devices for at least 90 days prior to screening\n* Diagnosis of medication overuse headache according to the ICHD-3 guidelines at the screening visit with the study physician\n* Traumatic Brain Injury ≤ 1 year before screening visit or worsening of migraine as noted by the screening study physician\n* Head or neck trauma within the past year causing neurological or musculoskeletal signs or symptoms requiring treatment\n* Any medical, neurologic, or psychiatric condition that the screening study physician deems would lead to difficulty complying with the protocol or negatively impact the safety profile of the interventions\n* Psychiatric hospitalization in the last 6 months\n* Receiving hospice or palliative care\n* History of carotid or vertebral artery dissection\n* Presence of carotid bruits\n* Presence of contraindications (relative or absolute) for spinal manipulation or mobilization where these procedures cannot be modified for safe administration and are consistent with those published by the World Health Organization (WHO) guidelines, including but not limited to:\n* Local spinal hypermobility\u002Finstability\n* Conditions causing general spinal hypermobility, such as Marfan, Ehlers-Danlos syndrome, and Osteogenesis imperfecta\n* Malignancy of the spine or spinal cord\n* Frank disc herniation with signs of progressive neurological deficit\n* Spinal or intracanalicular hematomas Inflammatory spondyloarthropathies such as rheumatoid arthritis\n* Spinal fractures or dislocations\n* Avascular necrosis in an area of proposed joint manipulation\n* Bone-weakening disorders affecting the spine, such as benign bone tumors, infection, or osteoporosis\n* Vertebrobasilar insufficiency syndrome\n* Aneurysm involving a major blood vessel in an area of potential joint manipulation\n* History of stroke\n* Anticoagulant therapy or blood disorders cause significant bleeding tendency\n* Cervical spine congenital anomalies that affect the stability or neurologic integrity of the individual or history of cervical spine surgery\n* Either self-reported current alcohol or substance use disorder or current alcohol or substance use disorder documented by a treating medical provider within the past 6 months\n* Hormone replacement therapy for less than six months, or if prescriptions greater than 6 months in duration must be at a stable dose\n* Significant cognitive impairment that would impair participation in the trial\n* Currently pregnant or intention to become pregnant within the next six months",{"count":221,"type":21},[56],"Migraine, a chronic intermittent headache disorder, ranks in the top five causes of years lived with disability. One promising non-pharmacologic and integrative treatment for migraine may be chiropractic care due to the co-occurrence of migraine and musculoskeletal complaints. The goal of this application is to perform a pilot study of chiropractic care for episodic migraine to help inform the design of a future, full-scale pragmatic effectiveness trial.",[336],"Episodic Migraine",[203,338],"headache disorder",{"date":159,"type":34},{"date":341,"type":34},"2025-03-22",{"date":343,"type":21},"2027-04-30",{"name":40,"class":41},{"id":346,"slug":4,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":54,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":42},"100590813","NCT06972303","Mindfulness Meditation for Insomnia","A Pilot Feasibility and Acceptability RCT of an App-Based Mindfulness Meditation Intervention for Sleep Among Patients With Insomnia Disorder","Inclusion Criteria:\n\n* Age 18 years and older;\n* Chronic insomnia (≥ 3 nights\u002Fweek, for ≥ 3 months), defined by DSM-V or ICSD-3;\n* Have a primary complaint of difficulty falling asleep (sleep-onset insomnia) with self-reported sleep onset latency \\>20 min;\n* Insomnia Severity Index score ≥ 15;\n* Speak and understand English;\n* Have a smart device (phone or tablet) for mobile app installation\n\nExclusion Criteria:\n\n* Current diagnosis of sleep disorders other than insomnia (e.g., narcolepsy, restless leg syndrome, REM sleep behavior disorder, etc.);\n* Shift worker or routine night shifts;\n* Women with pregnancy or breastfeeding;\n* Regular (defined as twice a week or more) practice of mind-body interventions;\n* Patients with pace-maker or routinely using cardiovascular medications that have effects on heart rates (i.e., beta-blockers);\n* Neurological disorders (e.g. epilepsy, dementia, stroke, Parkinson's disease, neuroinfections, brain tumors, etc.) or current diagnosis of comorbid psychotic, substance use, and trauma-related disorders;\n* Currently under medications with sleep changing effects (e.g., anxiolytics\u002Fbenzodiazepines, selective serotonin reuptake inhibitors, hypnotics, etc.);\n* Hearing impairment or loss. Participants will be asked to report any medication for at least 2 weeks prior to study onset and during the study period.",{"count":314,"type":21},[247,271],"The investigators will conduct a 3-arm, pilot RCT where participants (N=30) will be randomized in a 1:1:1 design to 4 weeks of instructed bedtime MM practice at night (n=10) vs. uninstructed MM (n=10) vs. sleep hygiene education only (n=10). Aim 1 is to understand the feasibility and acceptability of the intervention and study procedures. Aim 2 is to explore patterns of within-group changes in sleep outcomes (i.e., insomnia severity and sleep quality). Patient-reported outcomes will be collected using a HIPAA-compliant electronic data management system (REDCap). Following informed consent, participants will receive links to REDCap surveys via email at Weeks 0, 4, 8, and 16. The investigators will also conduct a post-intervention interview at the end of Week 4 and an exit interview at Week 16. All participants will also receive a research kit with wearable devices and meet with our staff after they receive the kit for instructions. Data collected in the pilot RCT will help us to preliminarily identify tools for subjective measures and physiological signals to inform a future trial.",[355,356,357,358,359],"Sleep Initiation and Maintenance Disorders","Insomnia","Insomnia Chronic","Mindfulness","Telemedicine","2026-06-21",{"date":362,"type":34},"2026-06-23",{"date":364,"type":34},"2026-03-31",{"date":366,"type":21},"2028-12-29",{"name":40,"class":41},{"id":369,"slug":4,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":17,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":261},"100548651","NCT06423768","fMRI in CardiaC arrEst With Uncertain Prognosis","The fMRI in CardiaC arrEst With Uncertain Prognosis (FACE-UP) Study","FACE-UP","Inclusion Criteria:\n\n* survive of an in or out of hospital cardiac arrest\n\nExclusion Criteria:\n\n* Drug overdose\n* Opinion of medical team patient unlikely to survive more than 24 hours (severe concurrent medical illness, dilated and unreactive pupils, etc..)\n* Following verbal commands (MD or RN note) once TTM is complete and normothermia is achieved (Day 2 or 3; Day of admission is Hospital Day 0). If no TTM is administered, this can be assessed on Hospital Day 2.\n* Following verbal commands (study team assessment) at time of MRI\n* Family planning to WLST at time of enrollment\n* Non English speaker (okay if English not primary language, as long as they can understand it)\n* Permanent Contraindication to MRI (some kind of implanted metal)\n* Pregnant",{"count":376,"type":21},50,"The goal of this observational study is to determine whether specific advanced MRI measures are associated with functional outcomes in patients who are comatose after cardiac arrest. The main question\\[s\\] it aims to answer are:\n\nAim 1: Determine if stimulus-based functional MRI (fMRI)-measured activations are independently associated with favorable neurological outcomes after cardiac arrest\n\nAim 2: Determine if resting state functional MRI (rs-fMRI)-measured functional network connectivity is independently associated with favorable neurological outcomes after cardiac arrest.\n\nAim 3: Determine if diffusion tensor imaging (DTI)-measured white matter integrity is associated with favorable neurological outcomes after cardiac arrest.\n\nParticipants will undergo advanced MRI sequences at time of clinical MRI, and will be followed for 6 months post-arrest.",[379],"Cardiac Arrest","2026-06-18",{"date":382,"type":34},"2026-06-22",{"date":384,"type":34},"2024-05-16",{"date":386,"type":21},"2027-12-01",{"name":40,"class":41},{"id":389,"slug":4,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":54,"phases":396,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":261},"100641796","NCT07655284","STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy","STENT X Non-stent Genito-urinary Tract Reconstruction After Radical Cystectomy for Bladder Cancer - a Prospective, Randomized, Controlled and Multi Institutional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years old)\n* Muscle invasive bladder cancer or non-muscle invasive bladder cancer with indication of Radical Cystectomy\n* No concomitant surgeries like nephrectomies, colectomies or removal of other organs affected by the tumor (Except standard lymph node dissections as well as in men the prostate and seminal vesicles and in women the uterus, fallopian tubes, ovaries and vagina, that are considered part of the oncological radical cystectomy.)\n* Patients who have the capacity to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Simultaneous surgical procedures (except those specified in the inclusion criteria that are considered part of a routine radical cystectomy)\n* History of prior urinary diversion\n* Patients who decline to participate, lack understanding of the study's purpose, or are unable to provide informed consent\n* Cystectomy for other reasons than Bladder cancer\n* Previous radiation therapy in the pelvis for any reason\n* Extremely debilitated patients, malnourished individuals, or those undergoing palliative or hygienic cystectomy",{"count":395,"type":21},190,[397],"PHASE3","Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.",[400,401],"Bladder Cancer Requiring Cystectomy","Ureteral Stents",[403,404,405],"bladder cancer","cystectomy","ureteral stents","2026-06-17",{"date":382,"type":34},{"date":409,"type":21},"2026-09-01",{"date":411,"type":21},"2029-08-31",{"name":40,"class":41},{"id":414,"slug":4,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":49,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":54,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":436,"locationsCount":42},"100642670","NCT07650994","Movie-Watching Functional MRI for Mapping Brain Function in Neurosurgical Patients","Naturalistic Neuroimaging for Neurosurgical Brain Mapping","Inclusion Criteria:\n\n* Any sex, age between 21 to 70 years;\n* Known or suspected glioma (lesion) of the brain;\n* English speaking;\n* Patients with clinical fMRI scheduled (or pending scheduling) for presurgical planning at BWH ordered by a BWH clinician;\n* Passes prescreening and standard of care screenings for 3 Tesla MRI;\n* Willing to participate in the additional study scan and neuropsychological assessment visit;\n* Informed consent form signed by the subject or legally acceptable representative.\n\nExclusion Criteria:\n\n* Contraindications to MRI: Note: MRI screening will be performed by radiology staff as part of their standard process for their clinical scans and if subjects do not pass the screen, MRI will not be performed.\n* Pregnancy or possible pregnancy: Female participants under 55 (or 45 with menstrual cycle in the past 12 months) who may be pregnant. Per policy: potential subjects will be asked if they are pregnant and excluded if they say yes. If unsure, pregnancy testing will be performed. Any subjects with positive result will be excluded.","21 Years","70 Years",{"count":269,"type":21},[56],"This research will compare a new type of functional MRI (fMRI) called naturalistic viewing (also called movie watching) to standard clinical fMRI techniques. Standard clinical fMRI currently uses multiple tasks such as reading and responding to words or sentences to determine which areas of the brain are responsible for language. Surgeons can use this information to help plan brain surgeries. This research will help determine if the movie-watching fMRI is equivalent or better than the standard task-based fMRI. If so, it could be useful for planning patients' surgeries in the future, without the need for multiple tasks.",[425,426],"Glioma","Brain Tumor Adult",[428,429,430,431],"Movie Functional Magnetic Resonance Imaging","Clinical Functional Magnetic Resonance Imaging","Presurgical Planning","Presurgical Brain Mapping",{"date":382,"type":34},{"date":409,"type":21},{"date":435,"type":21},"2029-03-31",{"name":40,"class":41},{"id":438,"slug":4,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":51,"enrollmentInfo":443,"targetDuration":4,"studyType":54,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":453,"locationsCount":4},"100610475","NCT07228065","Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control","Pharmacy-led Intervention to Increase the Adoption of Fixed-dose Single Pill Blood Pressure Lowering Medications: Hybrid Effectiveness-Implementation Trial","Inclusion Criteria:\n\n* patients with documented hypertension diagnosis\n* had an elevated ambulatory blood pressure reading during the qualifying visit (systolic \\>140 mmHg or diastolic \\>90 mmHg\n* have an upcoming scheduled visit\n* have an active prescription for 1 blood pressure lowering medication with a fixed-dose combination (FDC) alternative\n\nExclusion Criteria:\n\n* have received a prescription for a FDC in the preceding two years\n* reside in a nursing home\n* have a documented allergy to any FDC components\n* are pregnant\n* preferred language is not English or Spanish, defined as documentation in the EHR indicating a primary language other than English or Spanish, or a documented request for an interpreter in a language other than Spanish\n* have a diagnosis of heart failure or renal failure, given that antihypertensive management in these populations typically requires disease-specific regimens and more frequent treatment adjustments",{"count":444,"type":21},720,[56],"The proposed study is an effectiveness-implementation hybrid type II trial designed to evaluate the impact of provider- and patient-directed interventions on FDC use. The trial will test the effectiveness of theory-driven nudges tailored to address provider and patient barriers. All interventions will be pharmacist-driven, with pharmacists delivering information via nudges to providers and via nudges or more intensive interventions (i.e., CPA) to patients. Data to evaluate outcomes will be extracted from electronic health records.",[448,449],"Hypertension","Primary Care",{"date":380,"type":34},{"date":257,"type":21},{"date":38,"type":21},{"name":40,"class":41},{"id":455,"slug":4,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":460,"minAge":81,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":54,"phases":463,"briefSummary":464,"conditions":465,"keywords":468,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":476,"locationsCount":42},"100598632","NCT07074015","IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens","IntelliWell: An AI-Assisted Microwell Platform for Label-Free Localization of Ultra-Rare Sperm in Non-Obstructive Azoospermia Micro-TESE Specimens","Inclusion Criteria:\n\n1. Male subjects presenting to Brigham and Women's or Faulkner urology clinic with infertility with clinical non-obstructive azoospermia (clinical diagnosis based on two semen analyses, physical examination, and hormonal testing).\n2. Male subjects undergoing micro-surgical testicular sperm extraction surgery at Brigham and Women's Hospital.\n3. Surgically extracted sperm which are not found to have clinically usable quantities of sperm after standard of care manual processing for which samples would otherwise be discarded and the procedure deemed unsuccessful.\n\nExclusion Criteria:\n\n1\\. Female subject (with whom male subjects intends to conceive with surgically extracted sperm) cannot or will not provide her informed consent for study participation. She will undergo ICSI at BWH with BWH embryology.","MALE",{"count":462,"type":21},20,[56],"This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell and, if sperm is found and verified by embryologists, it may be used for intracytoplasmic sperm injection (ICSI).",[466,467],"Infertility","Azoospermia",[469,470,471],"infertility","azoospermia","micro-TESE",{"date":382,"type":34},{"date":474,"type":34},"2026-04-16",{"date":386,"type":21},{"name":40,"class":41},{"id":478,"slug":4,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":54,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":42},"100352394","NCT03868293","Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial","Low Intensity Focused Ultrasound Treatment for Epilepsy: A Pilot Trial","LIFUS","Inclusion Criteria:\n\n* Subjects at least eighteen (18) years of age\n* Subjects with drug-resistant temporal lobe epilepsy whose seizures involve altered awareness (ie failed at least two trials of antiepileptic drugs for seizures), as determined by one of the BWH epilepsy neurologists based on clinical seizure semiology and\u002For EEG findings.\n* Subjects who experience at least 1-2 seizures per month on average, are aware of or have reliable caregivers who are aware of when seizures occur and can reliably log seizure frequency\n* Subjects who have the cognitive ability to read and understand the consent form, describe any potential symptoms experienced during or after treatments.\n\nExclusion Criteria:\n\n* Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with testing\n* Subjects with dementia or other progressive degenerative disease, delirium or active psychosis\n* Subjects with ferromagnetic materials in the head\n* Subjects with severe cardiac disease, increased intracranial pressure, or a Transcutaneous Electrical Nerve Stimulation (TENS) unit\n* Subjects who have primary generalized epilepsy or non-epileptic seizures\n* Subjects who have experienced status epilepticus in the 3 months leading up to enrollment in the study\n* Subjects (females) who are pregnant, or are of childbearing potential and not willing to use reliable birth control during the treatment period.\n* Subjects who are unable to get a brain MRI for any reason (implanted metal in body, inability to lie still)\n* Subjects with current brain tumors or an intracranial vascular lesion\n* Subjects with severe, uncontrolled medical problems, such as diabetes mellitus, hypertension, pulmonary or airway disease, heart failure, coronary artery disease, or any other condition that poses a risk for the subject during participation.\n* Subjects with holes in the treatment area of the skull from trauma or prior surgery\n* Subjects with pacemakers, medication pumps, and other implanted electronic hardware. If a subject has a working Vagal Nerve Stimulator in place, the device will be turned off prior to each treatment session and then turned back on after each session.",{"count":485,"type":21},10,[56],"The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.",[489],"Drug Resistant Epilepsy",{"date":380,"type":34},{"date":492,"type":34},"2019-02-07",{"date":494,"type":21},"2027-03-09",{"name":40,"class":41},{"id":497,"slug":4,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":54,"phases":503,"briefSummary":504,"conditions":505,"keywords":509,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":42},"100539177","NCT06300450","Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy","PAD-ALERT","Inclusion Criteria:\n\n* All patients ≥ 18 years old\n* Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology\n* Medical history entry, visit diagnosis, or problem list entry of PAD\n* Not prescribed LDL-C-lowering therapy\n\nExclusion Criteria:\n\n* Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded",{"count":20,"type":21},[56],"This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.",[506,507,508],"Peripheral Artery Disease","Peripheral Vascular Diseases","Dyslipidemias",[510,506,511,512],"Dyslipidemia","Peripheral Vascular Disease","Computerized Decision Support","2026-06-16",{"date":406,"type":34},{"date":516,"type":34},"2023-03-01",{"date":518,"type":21},"2026-12-30",{"name":40,"class":41},{"id":521,"slug":4,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":54,"phases":528,"briefSummary":529,"conditions":530,"keywords":546,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":261},"100431578","NCT04899908","Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone","Inclusion Criteria:\n\n* Participants must have a biopsy proven solid malignancy and at least one intracranial measurable lesion spanning ≥5mm in maximal unidimensional size and radiographically consistent with or pathologically proven to be a brain metastasis AND meet one of the following additional criteria regarding the primary site or nature of the intracranial disease:\n\n  * Melanoma with intracranial growth consistent with tumor progression despite immunotherapy\n  * Gastrointestinal primary\n  * HER2 positive breast cancer (subtype assessed using most representative tissue available in opinion of enrolling clinician and\u002For study PI)\n  * Cystic metastases\n  * Metastases ≥2cm in maximal unidimensional size\n  * Locally recurrent metastases after prior stereotactic radiation\n  * Locally recurrent metastases after prior whole brain radiation \\*Patients with metastases from melanoma, GI primaries, or HER2+ breast cancer, as well as those with cystic metastases or metastases ≥2cm in maximal unidimensional size, who have local recurrences after prior brain-directed radiation can only be treated in the strata permitting prior radiation (last two strata above)\n* Age ≥18 years at diagnosis of brain metastases\n* Estimated glomerular filtration rate of ≥ 60 mL\u002Fmin\u002F1.73m2\n* Karnofsky performance status of at least 70 (i.e. at minimum, \"cares for self\" but \"unable to carry on normal activity or do active work\")\n* Estimated survival based on extracranial disease of at least 3 months in the opinion of the enrolling clinician and\u002For study PI\n* Ability to understand and the willingness to sign a written informed consent document\n* The effects of AGuIX on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of the therapeutic component of study participation\n\nExclusion Criteria:\n\n* Participants who cannot undergo a brain MRI\n* Participants who cannot receive gadolinium\n* Participants with widespread, definitive leptomeningeal disease\n* Patients requiring radiation to either \\>10 targets (if naïve to whole brain radiation) or \\>20 targets (if whole brain radiation has been given previously) per the discretion of the treating clinician and\u002For study PI\n* Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study\n* In cohorts who have received prior brain-directed radiation, patients are not eligible for this study if they have active (at the time of protocol screening) brain metastases that require radiation that are in or within 1.0cm of the brainstem, eyes, optic nerves, or optic chiasm if the juxtaposed organ at risk (i.e. brainstem, eyes, optic nerves, or optic chiasm) has previously received either \\>6.0 Gy in a single fraction or, if prior radiation was fractionated, a cumulative dose in 2.0 Gy equivalents, using an alpha\u002Fbeta ratio of 2, of \\>40.0 Gy. In addition, all patients who have had prior brain-directed radiation, regardless of technique\u002Fdose\u002Ffractionation, are not eligible for the study until written approval is provided by the study\u002Fsite PI",{"count":527,"type":21},134,[271],"The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.",[531,532,533,301,534,535,536,537,538,539,540,541,542,543,544,545],"Brain Cancer","Brain Metastases","Melanoma","Breast Cancer","HER2-positive Breast Cancer","Colorectal Cancer","Gastrointestinal Cancer","SRS","SRT","Whole Brain Radiation","Stereotactic Radiation","AGuIX","Nanoparticle","Cystic","Brain Tumor",[531,532,533,301,534,535,536,537,538,539,547,541,542,543,544,545],"Whole brain radiation",{"date":406,"type":34},{"date":550,"type":34},"2021-09-15",{"date":552,"type":21},"2029-05",{"name":40,"class":41},{"id":555,"slug":4,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":11,"sex":49,"minAge":419,"maxAge":51,"enrollmentInfo":560,"targetDuration":4,"studyType":54,"phases":561,"briefSummary":562,"conditions":563,"keywords":568,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":574,"leadSponsor":576,"locationsCount":261},"100642199","NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).",{"count":123,"type":21},[397],"Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[564,565,566,401,567],"Opioid Consumption, Postoperative","Multimodal Analgesia","Ureteroscopy","Ureteral Stent-Related Symptoms",[565,569,570,405],"Postoperative Opioid Consumption","ureteroscopy","2026-06-12",{"date":406,"type":34},{"date":140,"type":21},{"date":575,"type":21},"2027-03-31",{"name":40,"class":41},{"id":578,"slug":4,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":11,"sex":49,"minAge":81,"maxAge":219,"enrollmentInfo":583,"targetDuration":4,"studyType":54,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":597,"leadSponsor":599,"locationsCount":42},"100615706","NCT07296094","Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial","To be eligible, individuals must be:\n\n* English speaking adults between ages 18 and 65\n* Diagnosis of DSM5 AUD, severe\n* Completion of inpatient withdrawal management (i.e. \"detox\") for AUD within 90 days of enrollment\n* Amenable to attending all psychotherapy and study visits at BWH CCI\n* Able to identify an individual who can act as points of contact during the trial\n* Have a friend or family member who can bring the participant home after the psilocybin sessions and stay overnight\n\nIndividuals with any of the following will be excluded:\n\n* • Any personal history of a psychotic disorder (schizophrenia, schizoaffective disorder, brief psychotic disorder, delusional disorder, schizophreniform disorder, substance-induced psychotic disorder or major depression with psychotic features) or any bipolar-spectrum disorder\n* Participants with a family history of first-degree relatives with psychotic disorder or bipolar-spectrum disorder\n* Participants who have a significant suicide risk as defined by current suicidal ideation (Columbia-Suicide Severity Rating Scale (C-SSRS) score 2 to 5) and\u002For recent (within the past 6 months) active suicidal ideation (C-SSRS score 4 or 5)\n* Participants who have a history of significant or serious adverse reaction to classic psychedelics\n* Homicidality within the last six months\n* History of DSM5 hallucinogen use disorder\n* Positive breath alcohol level at screening\n* Need for inpatient withdrawal management for alcohol at the time of screening\n* Current DSM5 opioid, cocaine, stimulant or sedative\u002Fhypnotic use disorder\n* Systolic blood pressure persistently above 165mmHg during screening\n* History of hypersensitivity to psilocybin\n* Use of psilocybin or other psychedelics with 5-HT2B activity in the prior 12 months\n* Significant EKG abnormalities including QTc prolongation defined as \\>450 ms for men and women, or a diagnosis or family history of Long QT syndrome.\n* History of any cardiac valvulopathy that raises the risk for participation as determined by the cardiology consultant\n* History of intracranial mass or bleed, seizure disorder other than alcohol withdrawal seizures, liver cirrhosis, renal failure, obstructive lung disease requiring supplemental oxygen, hyperthyroidism, narrow-angle glaucoma, uncontrolled cardiac arrythmias, heart failure\n* History of head trauma, stroke, or myocardial infarction in one year prior to enrollment.\n* Expected to require surgical treatment at any point during the trial\n* Liver dysfunction with LFTs \\> 3x upper normal limit at screening and Total bilirubin \\> 2.5x the upper normal limit\n* MRI contraindications (other ferromagnetic implants, body weight greater than 550 lbs., etc.)\n* Pregnant or breastfeeding\n* High risk for adverse emotional or behavioral reaction based on the opinion of the study investigators such as evidence of a personality disorder\n* Currently taking medications with serotonergic activity (other than SSRIs\u002FSNRIs); inhibitors of UGT1A9, UGT1A10, MAO, and aldehyde or alcohol dehydrogenase; antipsychotics (e.g., first and second generation); mood stabilizers (e.g., lithium, valproic acid); or significant inhibitors of UGT enzymes that metabolize psilocin\n* Selective serotonergic reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors are allowed if participants have been on stable doses of the medication(s) for at least 90 days prior to enrollment.\n* Currently receiving insulin for blood sugar management.",{"count":584,"type":21},36,[271],"This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg).",[588],"Alcohol Use Disorder",[590,591,592,593],"alcohol use disorder","psilocybin","inpatient withdrawal management","psychedelic",{"date":595,"type":34},"2026-06-15",{"date":595,"type":21},{"date":598,"type":21},"2030-02",{"name":40,"class":41},""]